CARDIOPHARMA ApS: Financial statements 2023
CVR: 13966273
Source: annual report 2023, Danish Business Authority
01/05/2022 – 30/04/2023
CARDIOPHARMA ApS (CVR 13966273) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 437,954 and a net result of DKK 1,018,640 compared with DKK 2,900,689 the year before. That is a decrease of 87.3% compared with the year before. Equity in the 2023 report amounted to DKK 27,999,993. The solvency ratio was 99.6%. The company had 1 employee in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK 437,954
- Profit/Loss
- DKK 1,018,640
- Equity
- DKK 27,999,993
- Total Assets
- DKK 28,121,993
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | 438K | 1M | 28M | 1 |
| 2022 | 0 | 3.4M | 2.9M | 28M | 1 |
| 2021 | 0 | 811K | 4.3M | 30.1M | 1 |
| 2020 | - | 2.4M | 1.6M | 26.2M | 1 |
| 2019 | - | 1.8M | 1.7M | 25M | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout CARDIOPHARMA ApS
CARDIOPHARMA ApS is a Danish company of the type Anpartsselskab based in Gentofte, founded in 1990. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named KM 455 ApS. The management consists of Niels Christian Fischer Petersen. The company is owned by Niels Christian Fischer Petersen. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK 4,336,132 and a net result of DKK 3,090,043 compared with DKK 1,968,388 the year before. Equity in the 2026 report amounted to DKK 31,593,726.